Microbial Genomics Market Report Scope & Overview:

The Microbial Genomics Market was valued at USD 2.50 Billion in 2025 and is expected to reach USD 9.20 Billion by 2035, growing at a CAGR of 13.92% from 2026-2035.

The Microbial Genomics Market is expected to witness growth in the coming years on account of the increasing incidences of infectious diseases around the world, growing adoption of next-generation sequencing techniques for pathogen identification, and rising need for profiling of antibiotics resistance. The improvements in genomic technologies will result in higher speed, accuracy, and reduced cost of sequencing of the microbial genome. Increasing governmental as well as institutional investments in antimicrobial resistance surveillance will also positively impact the demand for microbial genomics services. Lower sequencing costs will also make the technique easily available to laboratories and research centers.

In June 2025, bioMérieux agreed to acquire assets of Day Zero Diagnostics, strengthening its next-generation sequencing capabilities. The deal highlights growing integration of genomic sequencing and machine learning into antimicrobial resistance diagnostics, while established in vitro diagnostics companies increasingly pursue genomics acquisitions to expand their infectious disease testing portfolios and capabilities.

Microbial Genomics Market Trends

• Rising adoption of next-generation sequencing platforms for faster, more precise microbial genome analysis.

• Growing integration of microbial genomics into national antimicrobial resistance surveillance programs.

• Expansion of long-read and real-time nanopore sequencing for antibiotic resistance and pathogen identification.

• Increasing use of single-cell and high-throughput microbial genome barcoding techniques in research settings.

• Rising demand for customizable digital PCR and targeted NGS panels tailored to specific microbial applications.

• Growing application of microbial genomics in drug discovery and microbiome-based therapeutic development.

U.S. Microbial Genomics Market Outlook

The U.S. Microbial Genomics Market was valued at USD 0.85 Billion in 2025 and is expected to reach USD 2.85 Billion by 2035, growing at a CAGR of 12.86% from 2026-2035.

The U.S. Microbial Genomics Market continues to receive substantial support in terms of funding by the government for genomic epidemiology, surveillance of antimicrobial resistance, and studies on infectious diseases. Extensive microbial genomics sequencing and analysis is supported by a well-knit infrastructure consisting of medical schools, universities, public health laboratories, and research institutions specializing in the area. It is pertinent to note that the country is home to some of the best sequencing technology and genomics companies, thereby improving access to superior platforms and bioinformatics tools. Federal research initiatives along with infectious disease consortia have helped drive the adoption of microbial genomics in clinical settings as well.

In October 2024, Illumina introduced its MiSeq i100 Series sequencing systems, offering faster benchtop sequencing and simplified workflows. The platform supports small whole-genome sequencing in microbiology and targeted NGS panels for infectious diseases, helping laboratories address growing demands for efficient, high-throughput sequencing and shorter turnaround times across clinical and research applications.

Microbial Genomics Market Segment Analysis

• By Technology, the Sequencing segment dominated the Microbial Genomics Market with approximately 52.00% share in 2025, and is also the fastest growing with a CAGR of approximately 15.20%.

• By Products and Service, the Consumables segment dominated the Microbial Genomics Market with approximately 48.00% share in 2025, while the Systems and Software segment is the fastest growing with a CAGR of approximately 16.50%.

• By Application, the Diagnostics segment dominated the Microbial Genomics Market with approximately 40.00% share in 2025, while the Drug Discovery segment is the fastest growing with a CAGR of approximately 15.80%.

• By End-User, the Hospitals and Diagnostic Laboratories segment dominated the Microbial Genomics Market with approximately 38.00% share in 2025, while the Pharmaceutical and Biotechnology Companies segment is the fastest growing with a CAGR of approximately 16.00%.

By Technology, Sequencing dominates and grows fastest

Sequencing systems such as next generation and single molecule real time sequencing are the frontrunners in the Microbial Genomics Market. They form an integral part in the identification, analysis, and surveillance of microbes, their genome, and genetic functions. Advances in sequencing chemistry and instrumentations have made it possible for whole genome as well as targeted sequencing to become available to various clinical microbiology, public health and academia laboratories, thereby making sequencing the key underlying technology in most microbial genomics procedures.

This particular area is also experiencing the highest rate of expansion due to increased demand for personalized medicines, research interests in the field of microbiome studies and increased usage of sequencing technology in antibiotic resistance and pathogen classification studies. Single cell genomics, long read sequencing and multi-omic integration technologies have facilitated the understanding of disease mechanisms and cellular biology processes whereas real-time nanopore sequencing is able to detect antibiotic resistance much faster than the conventional phenotypic approach.

By Products and Service, Consumables dominates, and Systems and Software grows fastest

Consumables, including library preparation kits, reagents, and sequencing flow cells, represent the largest products and service category in the Microbial Genomics Market, reflecting the recurring, per-sample nature of consumable spending across every sequencing and PCR-based workflow. As sequencing volumes rise across clinical, research, and industrial applications, consumable purchasing scales directly with sample throughput, generating a steady, repeat-purchase revenue base that has made this segment the largest contributor to overall market value.

Systems and software are expanding fastest, driven by growing demand for bioinformatics platforms capable of managing the complex data-analysis and interpretation requirements associated with modern microbial genomics workflows. As sequencing throughput increases, laboratories are investing in integrated analytics software to classify bacterial species, detect resistance genes, and manage multi-omics datasets at scale, a shift that is elevating the strategic importance of software platforms relative to standalone hardware within overall laboratory technology budgets.

By Application, Diagnostics dominates, and Drug Discovery grows fastest

Diagnostic applications account for the largest share of the Microbial Genomics Market, reflecting the central role of pathogen identification and infectious disease characterization in routine clinical and public health microbiology. Genomic sequencing has become an increasingly standard tool for classifying bacterial species, tracking transmission patterns during outbreaks, and profiling antibiotic resistance genes, applications that generate recurring, high-volume testing demand across hospitals, reference laboratories, and public health agencies worldwide.

Drug discovery applications are growing fastest, supported by rising pharmaceutical and biotechnology investment in microbiome-based therapeutics and genomically informed antimicrobial development programs. As drug developers increasingly rely on microbial genomic data to identify novel therapeutic targets and understand host-microbiome interactions, demand for sequencing and analysis services tailored to drug discovery workflows continues to expand at a pace outstripping the broader application landscape.

By End-User, Hospitals and Diagnostic Laboratories dominate, and Pharmaceutical and Biotechnology Companies grow fastest

Hospitals and laboratories of diagnostics are considered to be the biggest market segment of users of microbial genomics since they perform a key role in large-scale detection and infection control tests. The mentioned organizations have all necessary clinical expertise, accreditation and volume of testing, which makes them suitable for replacement of instruments and provision of routine materials.

Pharmaceutical and biotech companies demonstrate the highest rates of growth because drug makers include microbial genomics into their research on antimicrobial resistance, microbiome treatments, as well as vaccine and antibodies development. Government and private financial investments into preparation for emergent diseases make a significant contribution into development of genomics sequencing in this market segment.

Regional Analysis

North America Microbial Genomics Market Insights

North America accounted for approximately 40.00% of the Microbial Genomics Market in 2025, the largest share among all regions, supported by robust research infrastructure, technological advancement, and rising institutional awareness of microbiome research. The United States drives the substantial majority of regional revenue, underpinned by substantial National Institutes of Health and Centers for Disease Control and Prevention funding for genomic epidemiology, the concentrated presence of leading sequencing platform vendors, and early adoption of metagenomic next-generation sequencing-based clinical diagnostics. Canada contributes a smaller but stable share, concentrated in academic and public health research institutions conducting microbial genome surveillance.

Research institutions across the region continue to expand microbial genomics-focused initiatives, from novel bacterial function-mapping methods developed at national laboratories to large, federally funded consortia investigating antibiotic resistance and emerging viral threats. Government grant funding directed at genomic epidemiology and vaccine-and-antibody platform development continues to sustain demand for sequencing instruments and bioinformatics tools across the region's research institutions. Mexico represents a comparatively smaller but expanding market, as regional research capacity and public health laboratory infrastructure gradually build out genomic surveillance capabilities.

Europe Microbial Genomics Market Insights

Europe is the second-largest region, being led by Germany, the United Kingdom, and France where joint efforts on combating antimicrobial resistance through action plans as well as an efficiently financed genomics system within public health systems drive a constant demand for microbial sequencing services. In Germany, a well-developed research institutes and biotech companies' network provides for a steady purchase of sequencing consumables and machines, whereas in the UK, the country's genomics programs in the field of public health continue to grow sequencing capabilities as part of their infectious disease preparation initiatives.

In France, with its strong research infrastructure and governmental support for infectious disease genomics research, the use of next generation sequencing remains to be supported constantly. In Southern and Eastern Europe (Italy and Spain), the sequencing capacity in research and public health facilities is growing due to the implementation of the healthcare development program, which includes laboratory upgrading. The work of distributors and research consortia is important for sequencing in these regions as well.

Asia Pacific Microbial Genomics Market Insights

Asia Pacific is the fastest-growing region in the Microbial Genomics Market, projected to expand at a CAGR of approximately 17.50% from 2026 to 2035, driven by rapidly expanding sequencing and research infrastructure, rising government healthcare investment, and growing awareness of microbiome and infectious disease research across China, Japan, and India. China represents the largest individual country market within the region, supported by an expanding domestic sequencing manufacturing base and growing government investment in genomic surveillance and biotechnology research infrastructure.

Japan and South Korea offer consistent demand driven by technology, which in turn is underpinned by the presence of mature avenues for research funding as well as the early deployment of novel sequencing systems. India will emerge as a key contributor to market growth on account of an increase in government funding for the sector, which in turn has led to more money being allocated towards research facilities and access to genomic sequencing equipment.

MEA & South America Microbial Genomics Market Insights

The Middle East & Africa region represents a smaller but strategically important share of the Microbial Genomics Market, led by Gulf Cooperation Council countries where rising government investment in healthcare and biotechnology research infrastructure has driven steady adoption of sequencing and genomic analysis tools. South Africa anchors demand across the broader African continent through a comparatively developed research and public health sector, though genomic surveillance capacity outside major research and public health institutions remains constrained by infrastructure and funding limitations across much of the wider region.

South America is expanding at a moderate but sustainable pace, supported by growing research institution investment in genomic surveillance and infectious disease research across Brazil and Argentina. Brazil represents the largest individual market in the region, with national public health institutions and academic research centers gradually building out sequencing capacity to support infectious disease monitoring, while budget constraints across the wider region continue to favor more cost-efficient PCR-based and targeted sequencing approaches over comprehensive whole-genome sequencing programs.

Market Dynamics

Growth Drivers: Rising Infectious Disease Prevalence and Genomic Technology Advancement

The factors influencing the growth of the market for microbial genomics include the increase in the prevalence of infectious diseases around the world, which will help in increasing the demand for genetic understanding of microbes, specifically pathogens, such as HIV, and pneumonia, where millions of people are affected by these diseases. The increase in prevalence of these diseases in the population will result in higher demand for tools of microbial genomics that are used in pathogen sequencing and in tracing their transmission.

Moreover, improvements in technology related to the field of genomics, including the use of next-generation sequencing systems, have made it possible to conduct thorough genomic studies. In the market, companies are entering the market through launching new sequencing systems, and single-cell DNA barcoding, which are high throughput tools for researchers. Besides, increased funding from the government towards antimicrobial resistance and genomic epidemiology consortia research is driving the institutional demand for the microbial genomics platform.

Restraints: Data Analysis Complexity and Lack of Standardization

The complexity involved in analyzing and interpreting microbial genomic data represents a significant restraint on broader market adoption, particularly among smaller laboratories and research institutions that lack dedicated bioinformatics expertise. Microbial genomic datasets are often large and complex, requiring specialized computational skills to translate raw sequencing output into clinically or scientifically actionable insights, a bottleneck that can slow adoption even where sequencing hardware itself is readily accessible.

The lack of standardization across microbial genomics workflows, data formats, and interpretation pipelines further complicates adoption, particularly for institutions seeking to compare results across different sequencing platforms or participate in multi-site surveillance networks. Smaller research institutions and public health laboratories, particularly in lower-resource settings, often lack the bioinformatics workforce and standardized protocols necessary to fully capitalize on sequencing investments, moderating the overall pace of market expansion in these environments.

Opportunities: Antimicrobial Resistance Surveillance and Emerging Market Expansion

The continuing rollout of domestic and global AMR surveillance programs creates an important opportunity for microbial genomics vendors. As governments and public health organizations come to require standardization in high-throughput WGS pipelines for pathogen surveillance, vendors who produce efficient and user-friendly sequencing and bioinformatics tools designed to support such programs are likely to benefit from large-scale procurements as their rollouts extend further into additional countries and health systems.

Another market opportunity can be found in developing R&D and public health markets in the Asia Pacific, Latin America, and parts of the Middle East and Africa. With increased spending on health systems and a higher awareness of the microbiome and infectious diseases research, there will be an expanded number of institutions using genomics and sequencing tools. Providers that invest in training programs, establish localized sales channels, and produce products at different pricing tiers can capture early mover advantages in these markets.

Recent Developments:

• 2024, QIAGEN launched custom microbial analysis tools, including a digital PCR assay design platform and QIAseq xHYB Custom Microbial Panels, expanding microbial genomic analysis across wastewater, food production, and pathogen testing.

• 2024, Oxford Nanopore Technologies introduced its Nanopore-Only Microbial Isolate Sequencing Solution, providing an end-to-end workflow from DNA extraction through analysis for complete microbial genome sequencing in infectious disease research.

• 2024, CosmosID introduced long-read and hybrid bacterial genome sequencing services in the United States, expanding its portfolio to support genome assembly and characterization for research and public health applications.

• 2024, Atrandi Biosciences launched the Flux microfluidic system and single-microbe DNA barcoding kit, enabling high-throughput labeling of thousands of microbial genomes and supporting single-cell DNA sequencing research applications.

Microbial Genomics Market Key Players

• Illumina, Inc.

• Thermo Fisher Scientific Inc.

• Oxford Nanopore Technologies plc

• Qiagen N.V.

• bioMérieux S.A.

• Pacific Biosciences of California, Inc.

• CD Genomics

• HiMedia Laboratories

• Takara Bio Inc.

• Novogene Co., Ltd.

• Agilent Technologies, Inc.

• Danaher Corporation

• BGI Genomics Co., Ltd.

• Eurofins Scientific SE

• Zymo Research Corporation

• Twist Bioscience Corporation

• Revvity, Inc.

• Element Biosciences, Inc.

• CosmosID Inc.

• Atrandi Biosciences

Microbial Genomics Market Report Scope: